|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.300 USD | +1.85% |
|
-2.65% | -4.90% |
| 08/05 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 17/04 | Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer | CI |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Revenues | - | - | - | 2.98M | 4.63M | ||
Total Revenues | - | - | - | 2.98M | 4.63M | ||
Cost of Goods Sold, Total | 70.55M | 86.72M | 148M | 155M | 161M | ||
Gross Profit | -70.55M | -86.72M | -148M | -152M | -156M | ||
Selling General & Admin Expenses, Total | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M | ||
Other Operating Expenses, Total | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M | ||
Operating Income | -84.47M | -117M | -191M | -202M | -208M | ||
Interest And Investment Income | - | - | - | 3.52M | 4.15M | ||
Net Interest Expenses | - | - | - | 3.52M | 4.15M | ||
Other Non Operating Income (Expenses) | -80.99M | 1.9M | 8.76M | 41K | 148K | ||
EBT, Excl. Unusual Items | -165M | -115M | -183M | -199M | -204M | ||
Gain (Loss) On Sale Of Investments | -391K | -8.13M | -2.38M | 3.02M | 2.91M | ||
Other Unusual Items | - | - | -13.5M | - | - | ||
EBT, Incl. Unusual Items | -166M | -123M | -198M | -196M | -201M | ||
Income Tax Expense | -486K | -948K | -279K | - | - | ||
Earnings From Continuing Operations | -165M | -122M | -198M | -196M | -201M | ||
Net Income to Company | -165M | -122M | -198M | -196M | -201M | ||
Net Income - (IS) | -165M | -122M | -198M | -196M | -201M | ||
Preferred Dividend and Other Adjustments | 18.75M | 20.19M | - | - | - | ||
Net Income to Common Incl Extra Items | -184M | -142M | -198M | -196M | -201M | ||
Net Income to Common Excl. Extra Items | -184M | -142M | -198M | -196M | -201M | ||
Per Share Items | |||||||
Net EPS - Basic | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 | ||
Basic EPS - Continuing Operations | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 | ||
Basic Weighted Average Shares Outstanding | 12.97M | 33.89M | 90.97M | 119M | 149M | ||
Net EPS - Diluted | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 | ||
Diluted EPS - Continuing Operations | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 | ||
Diluted Weighted Average Shares Outstanding | 12.97M | 33.89M | 90.97M | 119M | 149M | ||
Normalized Basic EPS | -7.97 | -2.11 | -1.25 | -1.05 | -0.86 | ||
Normalized Diluted EPS | -7.97 | -2.11 | -1.25 | -1.05 | -0.86 | ||
Supplemental Items | |||||||
EBITDA | -83.91M | -114M | -187M | -196M | -201M | ||
EBITA | -84.47M | -117M | -191M | -202M | -208M | ||
EBIT | -84.47M | -117M | -191M | -202M | -208M | ||
EBITDAR | -78.8M | -101M | -168M | -172M | -167M | ||
Total Revenues (As Reported) | - | - | - | 2.98M | 4.63M | ||
Effective Tax Rate - (Ratio) | 0.29 | 0.77 | 0.14 | - | - | ||
Current Domestic Taxes | 138K | 16K | - | - | - | ||
Total Current Taxes | 138K | 16K | - | - | - | ||
Deferred Domestic Taxes | -624K | -964K | -279K | - | - | ||
Total Deferred Taxes | -624K | -964K | -279K | - | - | ||
Normalized Net Income | -103M | -71.65M | -114M | -124M | -128M | ||
Supplemental Operating Expense Items | |||||||
General and Administrative Expenses | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M | ||
Research And Development Expense From Footnotes | 70.55M | 86.72M | 148M | 155M | 161M | ||
Net Rental Expense, Total | 5.11M | 13.51M | 18.46M | 24.24M | 34M | ||
Stock-Based Comp., COGS (Total) | - | 4.44M | 7.95M | 12.7M | 19.37M | ||
Stock-Based Comp., G&A Exp. (Total) | - | 2.02M | 5.96M | 13.36M | 9.9M | ||
Total Stock-Based Compensation | - | 6.46M | 13.91M | 26.07M | 29.27M |
- Stock Market
- Equities
- PRME Stock
- Financials Prime Medicine, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition